Critical ACE2 Determinants of SARS-CoV-2 and Group 2B Coronavirus Infection and Replication.


Journal

mBio
ISSN: 2150-7511
Titre abrégé: mBio
Pays: United States
ID NLM: 101519231

Informations de publication

Date de publication:
16 03 2021
Historique:
entrez: 17 3 2021
pubmed: 18 3 2021
medline: 2 4 2021
Statut: epublish

Résumé

The angiotensin-converting enzyme 2 (ACE2) receptor is a major severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) host range determinant, and understanding SARS-CoV-2-ACE2 interactions will provide important insights into COVID-19 pathogenesis and animal model development. SARS-CoV-2 cannot infect mice due to incompatibility between its receptor binding domain and the murine ACE2 receptor. Through molecular modeling and empirical

Identifiants

pubmed: 33727353
pii: mBio.03149-20
doi: 10.1128/mBio.03149-20
pmc: PMC8092278
pii:
doi:

Substances chimiques

Recombinant Proteins 0
Spike Glycoprotein, Coronavirus 0
Angiotensin-Converting Enzyme 2 EC 3.4.17.23

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI089728
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA260543
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI110700
Pays : United States

Informations de copyright

Copyright © 2021 Adams et al.

Références

Cell. 2020 Nov 12;183(4):1070-1085.e12
pubmed: 33031744
mBio. 2014 May 20;5(3):e01174-14
pubmed: 24846384
Cell Host Microbe. 2020 Jul 8;28(1):124-133.e4
pubmed: 32485164
Nat Microbiol. 2016 Nov 28;2:16226
pubmed: 27892925
Protein Cell. 2020 Oct;11(10):776-782
pubmed: 32749592
PLoS Biol. 2020 Dec 21;18(12):e3001016
pubmed: 33347434
Cell Rep. 2020 Jul 21;32(3):107940
pubmed: 32668216
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
J Virol. 2020 Oct 27;94(22):
pubmed: 32847856
Curr Protoc Bioinformatics. 2016 Jun 20;54:5.6.1-5.6.37
pubmed: 27322406
Science. 2021 Jan 8;371(6525):172-177
pubmed: 33172935
Nat Med. 2020 Apr;26(4):450-452
pubmed: 32284615
J Virol. 2008 Aug;82(15):7264-75
pubmed: 18495771
RNA Biol. 2011 Mar-Apr;8(2):270-9
pubmed: 21593585
Cell. 2020 Aug 6;182(3):744-753.e4
pubmed: 32553273
Lancet Microbe. 2020 Sep;1(5):e218-e225
pubmed: 32838346
Cell. 2020 Jul 23;182(2):429-446.e14
pubmed: 32526206
J Virol. 2007 Nov;81(22):12135-44
pubmed: 17804504
Nature. 2020 May;581(7807):221-224
pubmed: 32225175
Sci Transl Med. 2020 Apr 29;12(541):
pubmed: 32253226
J Virol. 2020 Mar 17;94(7):
pubmed: 31996437
J Virol. 1996 Jun;70(6):3947-60
pubmed: 8648732
Science. 2020 Sep 25;369(6511):1603-1607
pubmed: 32732280
mBio. 2018 Mar 6;9(2):
pubmed: 29511076
Nature. 2020 Jul;583(7815):282-285
pubmed: 32218527
Proc Natl Acad Sci U S A. 2016 Mar 15;113(11):3048-53
pubmed: 26976607
Proc Natl Acad Sci U S A. 2020 May 26;117(21):11727-11734
pubmed: 32376634
Heliyon. 2020 Sep;6(9):e04818
pubmed: 32904785
J Virol. 2020 Feb 14;94(5):
pubmed: 31801868
Nature. 2020 Jul;583(7818):830-833
pubmed: 32380511
Arch Gesamte Virusforsch. 1974;44(3):298-302
pubmed: 4365902
Science. 2020 May 29;368(6494):1016-1020
pubmed: 32269068
Nature. 2020 Oct;586(7830):560-566
pubmed: 32854108
J Exp Med. 2020 Dec 7;217(12):
pubmed: 32750141
Nat Med. 2015 Dec;21(12):1508-13
pubmed: 26552008
Nature. 2020 May;581(7807):215-220
pubmed: 32225176
J Virol. 2014 May;88(9):5195-9
pubmed: 24574399

Auteurs

Lily E Adams (LE)

Department of Microbiology & Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

Kenneth H Dinnon (KH)

Department of Microbiology & Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

Yixuan J Hou (YJ)

Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

Timothy P Sheahan (TP)

Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

Mark T Heise (MT)

Department of Microbiology & Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA mark_heisem@med.unc.edu rbaric@email.unc.edu.
Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Rapidly Emerging Antiviral Drug Discovery Initiative, University of North Carolina, Chapel Hill, North Carolina, USA.

Ralph S Baric (RS)

Department of Microbiology & Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA mark_heisem@med.unc.edu rbaric@email.unc.edu.
Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Rapidly Emerging Antiviral Drug Discovery Initiative, University of North Carolina, Chapel Hill, North Carolina, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH